Niagen Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NAGE and other ETFs, options, and stocks.

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). 

CEO
Robert N. Fried
CEORobert N. Fried
Employees
104
Employees104
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1999
Founded1999
Employees
104
Employees104

NAGE Key Statistics

Market cap
501.98M
Market cap501.98M
Price-Earnings ratio
26.25
Price-Earnings ratio26.25
Dividend yield
Dividend yield
Average volume
909.58K
Average volume909.58K
High today
$6.60
High today$6.60
Low today
$6.21
Low today$6.21
Open price
$6.51
Open price$6.51
Volume
181.73K
Volume181.73K
52 Week high
$14.69
52 Week high$14.69
52 Week low
$5.24
52 Week low$5.24

Stock Snapshot

As of today, Niagen Bioscience(NAGE) shares are valued at $6.29. The company's market cap stands at 501.98M, with a P/E ratio of 26.25.

On 2026-01-14, Niagen Bioscience(NAGE) stock moved within a range of $6.21 to $6.60. With shares now at $6.29, the stock is trading +1.3% above its intraday low and -4.7% below the session's peak.

Trading activity shows a volume of 181.73K, compared to an average daily volume of 909.58K.

Over the past 52 weeks, Niagen Bioscience(NAGE) stock has traded between a high of $14.69 and a low of $5.24.

Over the past 52 weeks, Niagen Bioscience(NAGE) stock has traded between a high of $14.69 and a low of $5.24.

Analyst ratings

100%

of 6 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own NAGE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .